Navigation Links
Histogen Wins Appellate Court Hearing in SkinMedica Patent Case
Date:8/26/2013

San Diego, CA (PRWEB) August 26, 2013

Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, today announced that the United States Court of Appeals for the Federal Circuit has affirmed a lower court decision that the Company does not infringe patents in the lawsuit that SkinMedica, Inc. filed against Histogen in 2009.

SkinMedica had previously sued the Company for infringement of United States Patent Nos. 6,372,494 (titled “Methods of making conditioned cell culture medium compositions”) and 7,118,746 (titled “Conditioned cell culture medium compositions and methods of use”). In 2011, the United States District Court for the Southern District of California granted the Company’s Motion for Summary Judgment, confirming a finding of noninfringement. SkinMedica appealed the Summary Judgment Order, and on August 23, 2013 was rebuffed again by the Federal Circuit.

“We are excited to have confirmation from the Federal Circuit Court of Appeals that Histogen’s technology is unique, and outside of SkinMedica’s patent rights,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “We look forward to continuing the rapid revenue growth we’re seeing in our skincare business through our current partners, bringing on new partners in the near future, and expanding the skin care line to other aesthetic applications.”

Histogen’s proprietary human multipotent cell conditioned media is the key ingredient in the ReGenica line of skincare products within the United States, and will be incorporated into additional cosmetic products in various countries through promising partnerships.

The Federal Circuit Court of Appeals affirmed the grant of Motion for Summary Judgment in case 2012-1560 following a hearing on May 9, 2013. A copy of the appellate court opinion is available upon request.

About Histogen
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Histogen Creates PUR Biologics, a Joint Venture Developing Next-Generation, Biologic Solutions in Orthopedic Applications
2. Genetic Testing Explodes after Supreme Court Patent Decision
3. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
4. Honey Bee Beekeeping Class at North Island College’s Courtenay Campus
5. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
6. Bed Bugs are On The Rise in Courts and Apartment Complexes; My Cleaning Products Offers Complimentary Samples of Its Bed Bug Spray To Bed Bug Victims
7. Non-Toxic Bed Bug Spray Offers Complimentary Sample to Court After a Man Infected It With Bed Bugs, My Cleaning Products Explains How Others Could Get a Sample
8. Indoor Air Quality Professionals Provide New Expert Witness Services To Help Mold Victims Get Mold Claims Approved and Win in Court, AGCEnvironmental Explains How
9. Case Zeltiq - CLINIPRO: The Court Upholds Clinipro - LipoCryo Claim
10. Three Blockbuster Patent Cases at the Supreme Court This Term
11. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: ... second quarter financial results on Thursday, July 30, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:7/27/2015)... 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ... commercializing products for the treatment of cancer, today provides ... it has closed a $1,000,000 unit offering private placement.  ... units of the Company at a price of $0.06 ... share and one common share purchase warrant.  Each whole ...
(Date:7/27/2015)... London, UK (PRWEB) , ... July 27, 2015 , ... ... stable growth over the past few years in the EU. For instance, it surpassed ... approximately the EUR 92 million mark in 2010. Germany is a major producer, while ...
(Date:7/27/2015)...   Inocucor Technologies Inc ., the agriculture ... farmers, has received a notice of allowance from ... patent application to protect Inocucor consortia and unique ... yields on farms and in greenhouses. ... microbial consortium and its fermentation byproducts, which are ...
Breaking Biology Technology:Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Quest PharmaTech Closes $1,000,000 Private Placement 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... 29 BioSpace added Kansas to its annual promotional campaign ... , , , ... , , ... The leading employment Web site ...
... July 29 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... GlaxoSmithKline (NYSE: GSK ) related to the designation as a development ... will develop the drug to Phase 2 proof-of-concept, at which time GSK has ... , , ...
... , July 28 Dendreon Corporation (Nasdaq: ... pivotal Phase 3 IMPACT study in the New England ... statistically significant improvement in overall survival compared to control in ... cancer (mCRPC). The manuscript is published in the July ...
Cached Biology Technology:BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 2Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 3New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 2New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 3New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 4New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 5New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 6
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... an important role in longevity, with longer-lived rodents showing ... metabolism, a new study has found. , The study ... metabolism, the shorter its life, and vice versa, said ... hormones that regulate metabolic rate. , "Thyroid hormones ...
... methane, a greenhouse gas, at rates that appear to be ... a positive feedback to climate warming, said Katey Walter, in ... project is the first time this type of bubbling has ... missing a very large and important component of lake emissions ...
... and regions are transitioning from deforestation to afforestation, raising ... a whole, according to researchers advancing a more sophisticated ... looks beyond simply how much of a nation's area ... timber, biomass, and captured carbon within the area. ...
Cached Biology News:Longer-lived rodents have lower levels of thyroid hormone 2Siberian lakes burp 'time-bomb' greenhouse gas 2End of deforestation in view? Experts advance new way to size up global forest resources 2End of deforestation in view? Experts advance new way to size up global forest resources 3End of deforestation in view? Experts advance new way to size up global forest resources 4End of deforestation in view? Experts advance new way to size up global forest resources 5End of deforestation in view? Experts advance new way to size up global forest resources 6
... delivery of siRNA while maintaining high cell ... 96 samples simultaneously , Fast: ... to post-electroporation incubation , Highly ... Designed for use with the Bio-Rad Gene ...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: